Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986207 plus nivolumab and ipilimumab versus nivolumab and ipilimumab as first-line treatment for stage IV non-small cell lung cancer
2021-000039-29Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of BMS-986207, nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival in participants with tumors expressing PD-L1 >= 1% based on RECIST v1.1 by blinded independent central review. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-000039-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000039-29.